Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...
Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...
Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...
Many people living with focal onset seizures (FOS) fail to achieve seizure freedom, even after taking two or more ...
Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...
New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment ...
Median Reduction of Seizure Frequency of 35.7% Over Placebo was Achieved in the 60 mg Treatment Arm Neurological Effects and Other Adverse Effects (AEs) Similar to Placebo NEW YORK, Jan. 30, 2023 ...
If you have a certain kind of seizure that occurs with epilepsy, your doctor may prescribe Oxtellar XR for you. It’s a prescription drug used to treat focal onset seizures in adults and some children.
Patients with focal nonmotor seizures experience a "disproportionate delay to diagnosis" compared with those with focal motor seizures, especially among teens, new research suggests. Retrospective ...
Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback